According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “
Shares of NYSE ANIX traded down $0.06 during midday trading on Monday, reaching $4.21. The company’s stock had a trading volume of 1,897 shares, compared to its average volume of 64,430. ITUS has a fifty-two week low of $2.96 and a fifty-two week high of $6.86.
ITUS (NYSE:ANIX) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.23) earnings per share (EPS) for the quarter.
In other news, Director Lewis H. Titterton, Jr. bought 50,000 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average cost of $4.09 per share, for a total transaction of $204,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arnold M. Baskies bought 10,000 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were purchased at an average price of $4.28 per share, for a total transaction of $42,800.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 74,900 shares of company stock worth $310,638.
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Recommended Story: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.